Summary by Moomoo AI
Virpax Pharmaceuticals, Inc. (VRPX) has reported a transaction involving Chief Scientific Officer Sheila Mathias. The transaction took place on January 29, 2024. However, the announcement did not disclose the number of shares transacted, the nature of the shares, the transaction price, or the total value of the shares. Additionally, the number of shares held by Mathias after the transaction was not provided. This information is typically relevant for investors to assess the confidence of company insiders in the firm's prospects.